After entering the CAR T space in February, Eli Lilly is “jumping into in vivo CAR-T with both feet” with the acquisition of ...

PHILADELPHIA and MELBOURNE, Australia, April 21, 2026 /PRNewswire/ -- Minaris, a global cell and gene therapy (CGT) contract development and manufacturing organization (CDMO) and multimodality biosafe ...

As demand for CAR T therapies strain traditional manufacturing, Autolus Therapeutics has tapped Cellares to evaluate whether that company’s automated Cell Shuttle platform can support expanded ...

The dosing of these two patients demonstrates Cellares’ GMP manufacturing and supply chain capabilities with their automated platform.

The pharma giant’s second CAR-T deal this year, this one worth up to $7 billion, further solidifies what the industry sees as ...

The MarketWatch News Department was not involved in the creation of this content. WELLINGTON, New Zealand and KINGSTON, Ontario, April 07, 2026 (GLOBE NEWSWIRE) -- BioOra Limited ("BioOra"), a ...

Avantor AVTR recently entered into a strategic partnership with BlueWhale Bio to accelerate innovation in CAR-T cell therapy manufacturing. The collaboration merges Avantor’s bioprocessing expertise ...

CAR T-cell therapy is a personalized treatment that uses a patient’s own immune cells to fight cancer, making it effective but unsuitable for mass production, which increases the cost. The complex ...

During a live event, Binod Dhakal, MD, discussed the rationale for choosing therapy given before CAR T-cell infusion in multiple myeloma.